‹
›
This content requires a premium subscription.
Please
log in
or
subscribe
to continue.
JAMA Ophthalmology Author Interviews
Cost-effectiveness of Aflibercept vs Bevacizumab-First Therapy for Diabetic Macular Edema
30
00:00:00
/ 00:13:02
30